| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2592640 | Regulatory Toxicology and Pharmacology | 2008 | 6 Pages |
Abstract
Lycopene produced by recombinant Escherichia coli was tested for subacute oral toxicity to determine its No-Observed-Adverse-Effect Level (NOAEL). Doses of 0, 200, 500 and 2000Â mg/kg body weight/day were administered daily by gavage to 10 rats/sex/group for 28 days. No statistically significant, dose-related effect on body weight gain, clinical signs or ophthalmoscopic parameters was observed in any treatment group. Likewise, no treatment-related or dose-related toxic effect was found in hematology, clinical chemistry, urinalysis, blood coagulation, organ weight, gross observation or histopathology. Thus, the NOAEL for lycopene derived from recombinant Escherichia coli was at least 2000Â mg/kg body weight/day.
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Wen-Chi Jian, Ming-Hsi Chiou, Yung-Tin Chen, Chi-Nan Lin, Mei-Chiao Wu, Chi-Jen Du, Cleo Chen-Pan,